A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
Focal Segmental Glomerulosclerosis (FSGS)
About this trial
This is an interventional treatment trial for Focal Segmental Glomerulosclerosis (FSGS)
Eligibility Criteria
Key Inclusion Criteria: Body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m^2), inclusive A total body weight greater than 50 kg Key Exclusion Criteria: History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply.
Sites / Locations
- ICON Salt Lake City
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Sequence A: VX-147
Sequence B: VX-147
Sequence C: VX-147
Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.